CAS: 687-38-7; Glycylserine

相似化合物

7361-43-5 3695-73-6 16354-58-8

上下游产品

CAS号67206-28-4 氯乙酰基-DL-丝氨酸 | CAS号91841-16-6 Serine,N-[(1,3-... | CAS号108849-83-8 methyl Z-glycyl... | CAS号3062-03-1 O-Benzyl-N-glyc... | CAS号109591-99-3 N-benzyloxycarb... | CAS号302-84-1 DL-丝氨酸 | CAS号56-40-6 甘氨酸

📜N-Benzyloxycarbonylglycyl-Dl-Serine 反应生成 甘氨酰-Dl-丝氨酸
参考文献:Epitaxial Growth Of Zno Films On Si(111)
标题:Epitaxial Growth Of Zno Films On Si(111)
摘要:在本文中,我们报告了利用脉冲激光沉积技术在硅基底上生长氧化锌薄膜的情况.这些薄膜直接沉积在硅(111)上,也使用了氮化铝和氮化镓薄缓冲层.所有薄膜都具有与基底法线对齐的 C 轴优先取向.使用氮化铝和氮化镓缓冲层的薄膜具有优先面内取向的外延,而直接生长在硅(111)上的薄膜则具有随机面内取向.由于薄膜中存在拉伸应变,拉曼模式的频率降低,带边光致发光峰发生红移.讨论了观测到的双轴应变的各种可能来源.
DOI:10.1557/jmr.2002.0361

专利信息

专利号:US-6451543-B1
优先权日:1998-08-31
标题:Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides
发明人：KOCHENDOERFER GERD G; HUNTER CHRISTIE L; KENT STEPHEN B H; BOTTI PAOLO
权利人:GRYPHON SCIENCES
摘要:The present invention relates to methods and compositions for lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides that are incorporated in a lipid matrix. The invention is exemplified in production of a prefolded membrane polypeptide embedded within a lipid matrix via stepwise chemoselective chemical ligation of unprotected peptide segments, where at least one peptide segment is embedded in a lipid matrix. Any chemoselective reaction chemistry amenable for ligation of unprotected peptide segments can be employed. Suitable lipid matrices include liposomes, micelles, cell membrane patches and optically isotropic cubic lipidic phase matrices. Prefolded synthetic and semi-synthetic membrane polypeptides synthesized according to the methods and compositions of the invention also permit site-specific incorporation of one or more detectable moieties, such as a chromophore, which can be conveniently introduced during synthesis. The methods and compositions of the invention have multiple uses. For example, they can be used to assay ligand binding to membrane polypeptides and domains comprising a receptor, and thus are extremely useful for structure/function studies, drug screening/selection/design, and diagnostics and the like, including high-throughput applications. The methods and compositions of the invention are particularly suited for FRET analyses of previously inaccessible membrane polypeptides.

专利号:US-10150803-B2
优先权日:2016-10-27
标 题:Method of preparing glucagon-like peptide-2 (GLP-2) analog
发明人：CHEN SHIH-LIN; HSIUNG TING-YU
权利人:CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO LTD; CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO LTD
摘要:The present invention relates a method of preparing a Glucagon-like peptide 2 (GLP-2) analog by gene recombination. The present invention provides an expression vector, which includes: (a) a nucleic acid sequence encoding tag protein; (b) a nucleic acid sequence encoding Smt3 protein (SEQ ID NO: 1); and (c) a nucleic acid sequence encoding linker peptide (SEQ ID NO: 2) and GLP-2 analog. The fusion protein expressed by the expression vector can be cleaved by thrombin, wherein the cleaving position is at the linker peptide, and then the GLP-2 analog is produced.

专利号:US-7183396-B2
优先权日:1999-06-15
标题:Linvin, a novel inhibitor of apoptosis protein
发明人：GOMES BRUCE C; KASOF GARRETT M; PROSSER JUDITH C
权利人:GOMES BRUCE C; KASOF GARRETT M; PROSSER JUDITH C
摘要:A novel isolated and purified human protein inhibitor of apoptosis, termed livin, is described. A cDNA sequence which encodes the native inhibitor of apoptosis (livin) is disclosed as well as the structural coding region and the amino acid residue sequence. Molecular sequences are provided for the design and synthesis of entities that modulate biological and/or pharmacological activity of the native biomolecule. Methods are provided which employ the sequences to identify compounds that modulate biological and/or pharmacological activity of the native biomolecule. Biologically-effective antisense molecules as well as dominant negative mutant versions of the livin protein which are suitable for therapeutic are also provided. The invention is also drawn toward the study, prevention, diagnosis, and treatment of pathophysiological disorders related to apoptosis.

专利号:US-11649285-B2
优先权日:2016-08-03
标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
发明人：KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
权利人:BIO TECHNE CORP
摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

专利号:EP-0185824-A1
优先权日:1984-12-28
标 题 :Stabilization of tetrahydrofolic acid and serine hydroxymethyltransferase in reaction mixtures for the enzymatic cynthesis of L-serine
发明人：HSIAO HUNG-YU; WEI TENA T
权利人:GENEX CORP
摘要:A method of stabilizing tetrahydrofolic acid and serine hydroxymethyltransferase in reaction mixtures for the enzymatic synthesis of L-serine by addition to the reaction mixture of a reducing agent or a mixture of reducing agents and by the addition of a high concentration of THF relative to a catalytic amount is disclosed.

专利号:US-10370455-B2
优先权日:2014-12-05
标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
发明人：MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
权利人:IMMUNEXT INC
摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.